Literature DB >> 23328135

Histologic and molecular characterization of lung cancer with tissue obtained by electromagnetic navigation bronchoscopy.

Duc Ha1, Humberto Choi, Francisco A Almeida, Andrea Arrossi, Jennifer Brainard, Joseph Cicenia, Carol Farver, Thomas Gildea, Michael S Machuzak, Peter Mazzone.   

Abstract

BACKGROUND: Electromagnetic navigation bronchoscopy (ENB) is a catheter-based adjunct to standard bronchoscopic techniques for the sampling of lung lesions. We sought to evaluate the adequacy of ENB-obtained samples for histologic subtyping of lung cancer, epidermal growth factor receptor (EGFR) mutations, and echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocations.
METHODS: We retrospectively analyzed consecutive patients who underwent ENB for the diagnosis of lung lesions between 2008 and 2011. In those proven to be a primary lung cancer by ENB, tissue adequacy for histologic subtyping was recorded. Accuracy was determined by comparison with resected specimens when available. Tissue adequacy for EGFR mutation and/or EML4-ALK analyses was also reviewed.
RESULTS: Sixty-five ENB cases resulted in a diagnosis of lung cancer. Tissues obtained were adequate for histologic subtyping in all 65 cases. Forty-three (66.2%) were diagnosed with adenocarcinoma, 19 (29.2%) with squamous cell carcinoma, 3 (4.6%) with small cell carcinoma. In 51 cases (78.5%), subtyping was performed by morphology alone, whereas 11 (21.5%) required immunohistochemical staining. Sixteen of 65 tumors underwent surgical resection. Concordance of histologic subtyping between ENB and surgical specimens was 87.5% (14 tumors). ENB-obtained samples from 15 patients with adenocarcinoma were sent for EGFR mutation analysis, of which 14 (93.3%) were adequate. Samples from 2 patients were evaluated for EML4-ALK gene rearrangements, both of which were adequate for analysis.
CONCLUSIONS: ENB is effective at obtaining tissue samples adequate for histologic subtyping, EGFR mutation, and EML4-ALK translocation analysis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23328135     DOI: 10.1097/LBR.0b013e31828197e9

Source DB:  PubMed          Journal:  J Bronchology Interv Pulmonol        ISSN: 1948-8270


  6 in total

1.  Paired diagnostic and pharmacodynamic analysis of rare non-small cell lung cancer cells enabled by the VerIFAST platform.

Authors:  Benjamin P Casavant; Lindsay N Strotman; Jacob J Tokar; Stephanie M Thiede; Anne M Traynor; J Scott Ferguson; Joshua M Lang; David J Beebe
Journal:  Lab Chip       Date:  2014-01-07       Impact factor: 6.799

2.  Tissue requirements in lung cancer diagnosis for tumor heterogeneity, mutational analysis and targeted therapies: initial experience with intra-operative Frozen Section Evaluation (FROSE) in bronchoscopic biopsies.

Authors:  Jeffrey S Iding; William Krimsky; Robert Browning
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

Review 3.  Advanced imaging (positron emission tomography and magnetic resonance imaging) and image-guided biopsy in initial staging and monitoring of therapy of lung cancer.

Authors:  Shaheen Islam; Ronald C Walker
Journal:  Cancer J       Date:  2013 May-Jun       Impact factor: 3.360

4.  The introduction of electromagnetic navigation bronchoscopy for the diagnosis of small pulmonary peripheral lesions in an Asian population.

Authors:  Ye Gu; Shanhao Chen; Jingyun Shi; Chunyan Wu; Zongmei Wen; Hong Shi; Baomei Wu; Xin Xu; Hao Wang
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 5.  Electromagnetic navigation bronchoscopy: clinical utility in the diagnosis of lung cancer.

Authors:  Luis M Seijo
Journal:  Lung Cancer (Auckl)       Date:  2016-10-12

Review 6.  [Advances of Electromagnetic Navigation Bronchoscopy for Peripheral Pulmonary Lesions].

Authors:  Qiuming Chen; Zhou An; Jun Cheng; Wang Lv; Jian Hu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-06-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.